Boehringer Ingelheim latest to sue US over drug price negotiation plan
Type 2 diabetes treatment Jardiance, which Boehringer shares with US drugmaker Eli Lilly, is considered among the most likely drugs to be chosen for the first round of negotiations.;
United States: Boehringer Ingelheim sued the U.S. government in an attempt to block a program that gives the Medicare health insurance plan the power to negotiate lower drug prices, joining other drugmakers and business groups claiming that it would stifle development of new medicines.
In a complaint filed on Friday in federal court in New Haven, Connecticut, the privately-held German drugmaker said the program violates the U.S. Constitution by giving federal regulators too much power to dictate drug prices.
The U.S. Department for Health and Human Services (HHS), which oversees the Medicare program for Americans age 65 and older, did not immediately respond to a request for comment.
The drug price negotiation program is part of President Joe Biden's signature Inflation Reduction Act (IRA).
Americans pay more for prescription medicines than people in any other country, and the program aims to save $25 billion annually by 2031 through price negotiations for the drugs most costly to Medicare.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.